Inscripta raises $55.5M to advance gene-editing tools

BOULDER — Inscripta Inc., a gene-editing technology company based in Boulder, said on Wednesday that it has closed a $55.5 million series C funding round led by Mérieux Développement and Paladin Capital Group.

Mérieux Développement is based in France with an office in Boston, and Paladin Capital Group is a venture-capital firm based in Washington, D.C.

Additional participants included all existing Inscripta investors: Venrock, Foresite, MLS Capital and NanoDimension.

At the close of last year, Inscripta introduced its MAD7 enzyme, which is available for commercial and academic researchers. The enzyme allows researchers to…